Preliminary clinical results of TCR-T cell therapy showing anti-cancer activity in a variety of solid tumors are positive

On September 13, 2021, Adaptimmune Therapeutics announced its T cell antigen receptor cell therapy (TCR-T) ADP-A2M4CD8 targeting MAGE-A4, the latest data from the Phase 1 clinical trial SURPASS in a variety of solid tumors

TCR-T cell therapy introduces a gene sequence encoding an antigen-specific TCR into T cells to improve the specific recognition of tumor cells by T cells, thereby exerting a killing effect

▲The principle of TCR-T cell therapy (picture source: Adaptimmune official website)

All patients enrolled in the SURPASS trial have advanced metastatic cancer and have received multiple systemic treatments in the past (median: 3; range: 1-6)

Remission was observed in 5 solid tumor indications (lung cancer, bladder cancer, gastroesophageal cancer, head and neck cancer and ovarian cancer);

One patient with ovarian cancer reported a complete remission, which remained in remission 6 months after the infusion;

The overall response rate (ORR) was 36%, and the disease control rate (DCR) was 86%;

The initial durability is encouraging

In terms of safety, 18 patients (72%) developed cytokine release syndrome (CRS) related to T cell infusion, most of which were of lower grade: grade 1 or 2 (n=14), grade 3 ( n=4)

The specific data is shown in the following table:

Picture source: reference [1]

Reference materials:

[1] Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial.

[2] https://